- Charles River Laboratories International ( NYSE: CRL ) and Nanoscope Therapeutics are collaborating for manufacturing gene therapies for vision disorders.
- Charles River will manufacture both plasmid DNA and viral vectors for late stage trials targeting degenerative ocular diseases with no known cure, the company said in a statement on Tuesday.
- Nanoscope will have access to manufacturing platforms and multiple Charles River CDMO centers of excellence, the company added.
- Nanoscope's optogenetic therapy uses a proprietary AAV2 vector to deliver Multi-Characteristic Opsin (MCO) genes into retinal cells to enable vision, CRL noted.
- CRL +3.66% to $213.11 premarket Oct. 18
For further details see:
Charles River rises on collaboration to make gene therapies for vision disorders